Researchers evaluated clinical and histopathologic features in patients with dermatomyositis and circulating MDA5 autoantibodies, as defined by commercial-based testing.
The approval was based on data from the ProDERM study, which evaluated the efficacy and safety of Octagam 10% in 95 adults with dermatomyositis.
In a study presented at the EULAR 2021 Virtual Congress, researchers evaluated the safety and efficacy of intravenous immunoglobulin therapy in adult patients with dermatomyositis.
This is the first report of hepatosplenic T-cell lymphoma in a patient with dermatomyositis treated with prednisolone and azathioprine.
Researchers assessed clinical features, muscle biopsy scores, and myositis-specific antibody profiles in juvenile dermatomyositis, and their association with disease outcomes and treatment responses in patients.
Researchers aimed to evaluate the feasibility of studying creatine in juvenile dermatomyositis and to determine the effect of creatine on muscle function and metabolism.
Study authors investigated the link between anti-P155/140 and lipodystrophy, and between anti-P155/140 and damage to the nailfold capillary system in children with juvenile dermatomyositis.
Researchers investigated the content validity of patient-reported outcome measures in patients with idiopathic inflammatory myopathies.
Experts highlight the need for cancer screening strategies in patients with rheumatic diseases.
Researchers determined whether a modified disease activity score (DAS) correlated with the validated DAS in patients with juvenile dermatomyositis.
